Last Price$61.4(0.0%)
Market Cap$7,773.1M
80.8%
Industry median - 82.6%
5Y Historical average - 79.1%
54.9%
Industry median - (165.5%)
5Y Historical average - 37.3%
46.1%
Industry median - (175.6%)
5Y Historical average - 33.1%
105.5%
Industry median - 86.2%
5Y Historical average - 92.3%
HALO Profitability Rating
HALO Profitability rating
9.7
HALO Profitability rating performance
HALO Profitability Metrics
Annual
Quarterly
LTM
Industry Median
5Y Historical Average
Benchmark
Competing with HALO Profitability
Overview
Ratings
Intrinsic Value
Valuation
Growth
Profitability
Health
Capital allocation
Momentum
Earnings
Dividends
Company name | Market Cap | Profitability rating | Gross Profit margin (LTM) | EBIT margin (LTM) | EBITDA margin (LTM) | Net Income margin (LTM) | FCF margin (LTM) | Earnings quality (FCF to Net Income) |
$7,773.1M | 9.7 | 80.8% | 54.3% | 63.7% | 43.7% | 46.1% | 105.5% | |
$124.8B | 6.8 | 86.1% | (2.2%) | 4.4% | (4.9%) | (7.2%) | 147.6% | |
$77.0B | 8.1 | 84.5% | 28.3% | 33.9% | 31.1% | 25.3% | 81.5% | |
$34.4B | 5.9 | 86.8% | (17.1%) | (2.1%) | (4.5%) | (9.4%) | 103.2% | |
$30.7B | 5.3 | 85.6% | (7.9%) | (8.6%) | (12.4%) | (1.9%) | 15.3% | |
$24.0B | 6.3 | 80.3% | (47.8%) | (13.2%) | (24.2%) | (8.4%) | 33.9% | |
$14.5B | 8.4 | 73.9% | 57.1% | 81.0% | 37.9% | 122.3% | 208.1% | |
$13.8B | 9.1 | 89.2% | 47.9% | 55.9% | 41.5% | 37.6% | 90.4% | |
$13.4B | 8.8 | 78.6% | 16.2% | 22.8% | 15.0% | 16.7% | 111.4% | |
$13.3B | 5.7 | N/A | N/A | N/A | N/A | N/A | 64.2% | |
$1,846.9M | 5.8 | 83.7% | (26.3%) | (22.0%) | (95.0%) | (31.4%) | 121.0% |
FAQ
What is the Halozyme Therapeutics, Inc. (HALO) gross profit margin?
The Halozyme Therapeutics, Inc. (HALO) gross profit margin is 80.8%, compared to the industry median of 82.6% and the 5-year historical average of 79.1%.
What is the Halozyme Therapeutics, Inc. (HALO) operating income margin?
The Halozyme Therapeutics, Inc. (HALO) operating income margin is 54.9%, compared to the industry median of (165.5%)) and the 5-year historical average of 37.3%.
What is the Halozyme Therapeutics, Inc. (HALO) Free Cash Flow (FCF) margin?
The Halozyme Therapeutics, Inc. (HALO) Free Cash Flow margin is 46.1%, compared to the industry median of (175.6%) and the 5-year historical average of 33.1%.
What is the Halozyme Therapeutics, Inc. (HALO) earnings quality?
The Halozyme Therapeutics, Inc. (HALO) earnings quality is 105.5%, compared to the industry median of 86.2% and the 5-year historical average of 92.3%.